卵巢刺激期间联合来曲唑用于IVF/ICSI:一项系统综述与荟萃分析
该系统综述与荟萃分析检索Medline、Cochrane和ClinicalTrials.gov至2021年8月,纳入31项研究(16项随机对照试验、15项观察性研究),评估来曲唑在IVF/ICSI卵巢刺激中联合应用的效果。低反应者联合来曲唑后活产率显著提高7%(95%CI 1%至13%,P=0.03),促性腺激素用量显著减少且获卵数未减少;正常反应者获卵数增加1.8个(95%CI 0.35至3.27,P=0.01),但活产率、临床妊娠率及卵巢过度刺激综合征率无显著影响。
要点
- 低反应者联合来曲唑活产率提高7%(95%CI 1%至13%,P=0.03),促性腺激素用量减少且获卵数未减少。
- 正常反应者联合来曲唑获卵数增加1.8个(95%CI 0.35至3.27,P=0.01),活产率无显著影响。
- 高反应者仅2项研究报告,活产率及临床妊娠率无影响;纳入研究均未报告新生儿结局。
核心结论
- 低反应者可能在IVF卵巢刺激期间从联合来曲唑中获益,而正常和高反应者使用来曲唑需更大规模、高质量研究进一步探讨。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Cochrane和ClinicalTrials.gov数据库至2021年8月,纳入31项研究(16项随机对照试验,15项观察性研究)。
主要发现
- 低反应者联合来曲唑后活产率显著提高7%(95%CI 1%至13%,P=0.03),促性腺激素用量显著减少,获卵数未减少。
- 正常反应者联合来曲唑后获卵数增加1.8个(95%CI 0.35至3.27,P=0.01),活产率、临床妊娠率及卵巢过度刺激综合征率无显著影响。
- 仅2项研究报告高反应者,显示对活产率或临床妊娠率无影响。
- 总体子宫内膜厚度受轻微影响,流产率和周期取消率未受来曲唑联合治疗影响。
- 纳入研究均未报告新生儿结局;随机对照试验证据质量高或中等,观察性研究证据质量低。
关键数值与推荐
- 低反应者:联合来曲唑活产率提高7%(95%CI 1%至13%,P=0.03)。
- 正常反应者:联合来曲唑获卵数增加1.8个(95%CI 0.35至3.27,P=0.01)。
- 正常反应者:活产率、临床妊娠率、卵巢过度刺激综合征率无显著影响。
- 高反应者:仅2项研究,活产率或临床妊娠率无影响。
临床怎么用
- 作者认为低反应者可能在IVF卵巢刺激期间从联合来曲唑中获益。
- 作者认为正常和高反应者使用来曲唑需更大规模、高质量研究进一步探讨。
局限性
- 纳入研究均未报告新生儿结局。
- 观察性研究的证据质量低。
- 仅2项研究报告高反应者。
- 正常和高反应者使用来曲唑需更大规模、高质量研究进一步探讨。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Letrozole reduces serum oestradiol by inhibiting the aromatase enzyme and has growing clinical indications in fertility. The available evidence of letrozole's role in ovarian stimulation for IVF and intracytoplasmic sperm injection (ICSI) and clinical outcomes was assessed. Medline, Cochrane, and ClinicalTrials.gov databases were systematically searched up until August 2021, including 31 studies (n = 16 randomized controlled trials [RCTs]; n = 15 observational studies). Live birth rate (LBR) in poor responders significantly increased by 7% (95% CI, 1% to 13%, P = 0.03) with letrozole co-treatment. Concomitantly, the gonadotrophin consumption was significantly reduced, without decreasing the number of retrieved oocytes. In normal responders, number of oocytes increased with 1.8 oocytes (95% CI 0.35 to 3.27, P = 0.01) with letrozole co-treatment. No significant effect on LBR, clinical pregnancy rate (CPR), or ovarian hyperstimulation syndrome rate was demonstrated. Only two studies reported on high responders and revealed no effect on LBR or CPR. Overall, the endometrium thickness was slightly affected, where as the, miscarriage rate and cancellation rate were unaffected by letrozole co-treatment. None of the included studies reported on neonatal outcomes. The quality of evidence was high or moderate in the RCTs and low in the observational studies. In conclusion, poor responders may benefit from co-treatment with letrozole during ovarian stimulation for IVF, whereas letrozole for normal and high responders requires further investigation with larger, high-quality studies.
引用
- Bülow NS, Dreyer Holt M, Skouby SO, et al. Co-treatment with letrozole during ovarian stimulation for IVF/ICSI: a systematic review and meta-analysis. Reprod Biomed Online. 2021. PMID: 35183444. doi:10.1016/j.rbmo.2021.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。